CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 2,135	$ 6,165
Operating expenses:
Cost of goods sold	620	2,590
Research and development	21,964	24,334
General and administrative	6,816	6,891
Restructuring	2,401
Total operating expenses	31,801	33,815
Operating loss	(29,666)	(27,650)
Other income, net	952	985
Non-cash interest expense on liability related to sales of future royalties and milestones	(1,982)
Net loss	$ (30,696)	$ (26,665)
Net loss per share:
Basic	$ (0.56)	$ (0.49)
Diluted	$ (0.56)	$ (0.49)
Weighted average shares:
Basic	54,588,090	53,872,038
Diluted	54,588,090	53,872,038
Other comprehensive income, net of tax of $0:
Change in unrealized gains on available-for-sale marketable securities	$ 69	$ 571
Total comprehensive loss	(30,627)	(26,094)
Collaborative revenue
Revenue:
Total revenue	788	2,750
Commercial supply revenue
Revenue:
Total revenue	640	3,191
Royalty revenue
Revenue:
Total revenue		125
Clinical compound revenue
Revenue:
Total revenue	84	$ 99
Other revenue
Revenue:
Total revenue	$ 623